PDF(Pubmed)
Abstract：
UNASSIGNED: In recent years, Delftia acidovorans has gained attention for its rare occurrence in patient infections. The literature consists mostly of case reports, necessitating further research to comprehensively understand risk factors, clinical characteristics, and management strategies.
UNASSIGNED: We conducted a retrospective cohort study involving patients diagnosed with Delftia acidovorans infection at a tertiary teaching hospital between January 2014 and December 2022. The data included demographic details, comorbidities, bacterial cultures, antibiotic susceptibility, and treatment outcomes.
UNASSIGNED: There were 26 patients diagnosed with Delftia acidovorans infection who were predominantly older with multiple comorbidities. Approximately 76.9% of Delftia acidovorans infection patients had polymicrobial infections. Twenty-one patients had received antibiotics within three months before they developed the Delftia acidovorans infection, and these antibiotics were primarily third-generation cephalosporins, glycopeptides and fluoroquinolones. Antibiotic susceptibility testing showed resistance to aminoglycosides and susceptibility to imipenem, meropenem, ceftazidime, and piperacillin/tazobactam. Treatment outcome showed a mortality rate of 11.5%, mainly in patients with malignancy and advanced age.
UNASSIGNED: Delftia acidovorans infections predominantly affect older patients with multiple comorbidities. In terms of antibiotic therapy, carbapenems, cephalosporins, and piperacillin/tazobactam with antipseudomonal activity could all be considered.
UNASSIGNED: We conducted a retrospective cohort study involving patients diagnosed with Delftia acidovorans infection at a tertiary teaching hospital between January 2014 and December 2022. The data included demographic details, comorbidities, bacterial cultures, antibiotic susceptibility, and treatment outcomes.
UNASSIGNED: There were 26 patients diagnosed with Delftia acidovorans infection who were predominantly older with multiple comorbidities. Approximately 76.9% of Delftia acidovorans infection patients had polymicrobial infections. Twenty-one patients had received antibiotics within three months before they developed the Delftia acidovorans infection, and these antibiotics were primarily third-generation cephalosporins, glycopeptides and fluoroquinolones. Antibiotic susceptibility testing showed resistance to aminoglycosides and susceptibility to imipenem, meropenem, ceftazidime, and piperacillin/tazobactam. Treatment outcome showed a mortality rate of 11.5%, mainly in patients with malignancy and advanced age.
UNASSIGNED: Delftia acidovorans infections predominantly affect older patients with multiple comorbidities. In terms of antibiotic therapy, carbapenems, cephalosporins, and piperacillin/tazobactam with antipseudomonal activity could all be considered.
摘要：
■近年来，Delftiaacidovorans因其在患者感染中的罕见发生而受到关注。文献主要由病例报告组成，需要进一步研究以全面了解风险因素，临床特征,和管理策略。
■我们在2014年1月至2022年12月之间在三级教学医院进行了一项回顾性队列研究，涉及被诊断为Delftiaacidovorans感染的患者。数据包括人口统计细节，合并症,细菌培养物,抗生素敏感性，和治疗结果。
■有26例患者被诊断为Delftiaacidovorans感染，主要是年龄较大，有多种合并症。大约76.9％的Delftiaacidovorans感染患者患有多微生物感染。21名患者在发生Delftiaacidovorans感染之前的三个月内接受了抗生素治疗，这些抗生素主要是第三代头孢菌素，糖肽类和氟喹诺酮类。抗生素药敏试验显示对氨基糖苷类的耐药性和对亚胺培南的敏感性，美罗培南,头孢他啶,还有哌拉西林/他唑巴坦.治疗结果显示死亡率为11.5%，主要见于恶性肿瘤和高龄患者。
■Delftiaacidovorans感染主要影响患有多种合并症的老年患者。在抗生素治疗方面，碳青霉烯类,头孢菌素,和哌拉西林/他唑巴坦具有抗假单胞菌活性都可以考虑。
■我们在2014年1月至2022年12月之间在三级教学医院进行了一项回顾性队列研究，涉及被诊断为Delftiaacidovorans感染的患者。数据包括人口统计细节，合并症,细菌培养物,抗生素敏感性，和治疗结果。
■有26例患者被诊断为Delftiaacidovorans感染，主要是年龄较大，有多种合并症。大约76.9％的Delftiaacidovorans感染患者患有多微生物感染。21名患者在发生Delftiaacidovorans感染之前的三个月内接受了抗生素治疗，这些抗生素主要是第三代头孢菌素，糖肽类和氟喹诺酮类。抗生素药敏试验显示对氨基糖苷类的耐药性和对亚胺培南的敏感性，美罗培南,头孢他啶,还有哌拉西林/他唑巴坦.治疗结果显示死亡率为11.5%，主要见于恶性肿瘤和高龄患者。
■Delftiaacidovorans感染主要影响患有多种合并症的老年患者。在抗生素治疗方面，碳青霉烯类,头孢菌素,和哌拉西林/他唑巴坦具有抗假单胞菌活性都可以考虑。
